Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.
Dr. Jan Joseph (Jos) Melenhorst obtained his PhD at the LUMC (Department of Hematology) on the pathogenesis of Aplastic Anemia. In 1998 he moved to Bethesda, Maryland, where he did his research ‐ first as a postdoc, later as a staff scientist ‐ in the laboratory of Dr. John Barrett at the National Institutes of Health, on the immunobiology of marrow failure syndromes, leukemic disorders, and allogeneic stem cell transplantation. In 2012 he was recruited by Dr. Bruce Levine and Dr. Carl June to the University of Pennsylvania, first as Deputy Director of their clinical manufacturing (cGMP) facility. After a year he was promoted to Director of Product Development & Correlative Sciences. In this role, he was at the cusp of the first ever CAR T cell therapy approved by FDA: Kymriah. Dr. Melenhorst is interested in understanding and improving the anti-tumor efficacy and safety of adoptively transferred chimeric antigen receptor-modified T cells through correlative, mechanistic, and functional genomics approaches.
Dr. Hanley is an assistant research professor of pediatrics and Director of the Cellular Therapy Laboratory at Children’s National Hospital. He oversees processing for standard of care stem cell transplantation as well as the development, manufacture, and testing of novel cell therapies for patients enrolled on clinical trials. Trained as an Immunologist. He has an extensive background and interest in cellular therapy and is passionate about improving regulations for cellular therapy, training the next generation of cell therapists, and facilitating the translation of new therapeutics. Over the past 13 years he has helped to translate more than 20 cell therapy protocols – ranging from mesenchymal stromal cells to cord blood virus-specific T cells and tumor-associated antigen specific T cells – into the clinic. He is on the board of directors of the Foundation for the Accreditation of Cellular Therapy (FACT), is an active inspector, is chair of FACT’s education committee, serves on their accreditation committee and is also on the immune effector cell standards subcommittee. He serves on the editorial boards of the journals Cytotherapy and Molecular Therapy: Methods and Clinical Development. In 2017, along with Drs Catherine Bollard and Russell Cruz, he founded Mana Therapeutics, a biotech company aimed at educating immune cells and eliminating cancer. In his free time he enjoys playing soccer, cooking, and traveling.
Devyn joined Sigilon Therapeutics in early 2017 as Chief Operating Officer and Head of Strategy. In this role, he has helped build the company to over 100 colleagues. Operational achievements include building out the CMC group and initiating GMP manufacturing of our lead program, building the quality systems and group to oversee the portfolio, keeping the portfolio moving through successful project management and portfolio oversight. In addition, he has led the build out of the corporate strategy, portfolio strategy and other key strategy elements. He joined Pfizer's Medicinal Sciences Division of R&D as Head of Business Operations & Strategy in 2016 overseeing both day to day business operations of the division, as well insuring implementable strategies are developed. Prior to this Devyn was Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D focused on developing and implementing core strategies in Winning by Design in Small Molecules as well as optimizing the ROI on novel technology inventions.
Ian McNiece, PhD is VP of Research and Development at Aegle Therapeutics, which is based in Miami FL. He joined Aegle in 2017 and is responsible for the Manufacturing, Regulatory and Development efforts of the company. Aegle is developing extracellular vesicles (EVs) from MSCs to treat severe dermatological conditions, including burns and epidermolysis bullosa (EB). He received a Ph.D. in physiology in 1986 from the University of Melbourne undertaking his thesis work at the Peter MacCallum Cancer Institute. He was appointed to the position of Director of the Division of Biomedical Sciences Johns Hopkins in Singapore in 2004. At Miami his research focused on the use of stem cells for repair of cardiac tissue including the manufacture of MSCs for clinical trials. His research has focused on aspects of stem cell biology and in particular control of proliferation and differentiation of stem cells by growth factors and stromal cells. Much of his work has studied aspects of stem cells in clinical marrow and stem cell transplantation leading to clinical trials in mobilization and ex vivo expansion.